Abstract:BackgroundThere have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatitis testing guidance and in particular the feasibility of proposed recommendations, we undertook a survey across a range of organisations engaged with hepatitis testing in low- and middle-income countries (LMICs). Our objective was to describe current hepatitis B and C testing practices across a range of settings in different countries, as well as key barriers or challenges encountered and proposed solutions to promote testing scale-up.MethodsHepatitis testing programmes in predominantly LMICs were identified from the WHO Global Hepatitis Programme contacts database and through WHO regional offices, and invited to participate. The survey comprised a six-part structured questionnaire: general programme information, description of hepatitis testing, treatment and care services, budget and funding, data on programme outcomes, and perceptions on key barriers encountered and strategies to address these.ResultsWe interviewed 22 viral hepatitis testing programmes from 19 different countries. Nine were from the African region; 6 from the Western Pacific; 4 from South-East Asia; and 3 from Eastern Europe. All but four of the programmes were based in LMICs, and 10 (45.5%) were supported by non-governmental or international organizations. All but two programmes undertook targeted testing of specific affected populations such as people living with HIV, people who inject drugs, sex workers, health care workers, and pregnant women. Only two programmes focussed on routine testing in the general population. The majority of programmes were testing in hospital-based or other health facilities, particularly HIV clinics, and community-based testing was limited. Nucleic acid testing (NAT) for confirmation of HCV and HBV viraemia was available in only 30% and 18% of programmes, respectively. Around a third of programmes required some patient co-payment for diagnosis. The most commonly identified challenges in scale-up of hepatitis testing were: limited community awareness about viral hepatitis; lack of facilities or services for hepatitis testing; no access to low cost treatment, particularly for HCV; absence of national guidance and policies; no dedicated budget for hepatitis; and lack of trained health care and laboratory workers.ConclusionsAt this early stage in the global scale-up of testing for viral hepatitis, there is a wide variation in testing practices and approaches across different programmes. There remains limited access to NAT to confirm viraemia, and patient self-payment for testing and treatment is common. There was consensus from implementing organizations that scale-up of testing will require increased community awareness, health care worker training, development of national strategies and guidelines, and improved access to low cost NAT virological testing.

[Progress on the study of enteric adenovirus in young children].

Individualizing revascularization for peripheral arterial disease.

Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update

Hepatitis elimination by 2030: Progress and challenges

Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps

Global Elimination of Hepatitis C Virus

Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies

How Possible Is the Elimination of Viral Hepatitis? An Analysis Based on the Global Burden of Disease from Hepatitis B and C, 1990–2019

Global burden of hepatitis B virus: current status, missed opportunities and a call for action

Hepatitis B: Overview of the Burden of Disease in the Asia‐Pacific Region

Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Present and future management of viral hepatitis

[Multivariate analysis of acute leukemia].

Global Epidemiology of Hepatitis B Virus (HBV) Infection

Securing sustainable funding for viral hepatitis elimination plans

Advances in treatment and prevention of hepatitis B

The association between methicillin resistant staphylococcus aureus colonization and mortality in Chinese nursing home older adults: a 2-year prospective cohort.

Addressing viral hepatitis in the opiate substitution setting: An integrated nursing model of care

Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries

Countdown to 2030: Eliminating Hepatitis B Disease, China